39 unknown, 16 completed, 3 recruiting, 3 terminated. 62 Phase 1, 32 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 62 | Unknown 39, Completed 16, Recruiting 3, Terminated 3, Active not recruiting 1 |
| Phase 2 | 32 | Unknown 25, Completed 3, Recruiting 2, Active not recruiting 1, Terminated 1 |
Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 45 | 2026-09-21 | 2026-11-09 |
| Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 56 | 2026-03-05 | 2026-03-18 |
| The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer Adebrelimab + Apatinib + Lrinotecan liposome - Advanced Gastric Cancer | Phase 1 / Phase 2 | Unknown | Xianglin Yuan | 66 | 2024-09-30 | 2024-09-19 |
| A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies Adebrelimab, Apatinib, Gemcitabine - Biliary Tract Malignancies | Phase 1 | Recruiting | First Affiliated Hospital of Fujian Medical University | 35 | 2023-12-23 | 2024-04-30 |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma adebrelimab, camrelizumab plus apatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 52 | 2023-07-01 | 2024-02-21 |
| A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer Camrelizumab and Apatinib Plus GP - Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 49 | 2023-04-27 | 2026-06-22 |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Azacitidine Injection, Dasatinib, Linperlisib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 116 | 2022-09-30 | 2022-11-09 |
| A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants Rivoceranib - Healthy | Phase 1 | Completed | Elevar Therapeutics | 60 | 2021-12-30 | 2022-04-18 |
| Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer Apatinib Mesylate, Albumin-Bound Paclitaxel - Advanced Triple Negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fujian Cancer Hospital | 29 | 2021-10-01 | 2024-09-19 |
| Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. Apatinib, Irinotecan, Temozolomide - Neuroblastoma | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 111 | 2021-08-26 | 2026-11-10 |
| Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC Camrelizumab; apatinib; carboplatin; etoposide - Extensive Stage Small Cell Lung Cancer | Phase 1 | Unknown | Zhou Chengzhi | 36 | 2021-01-27 | 2021-08-12 |
| IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib - Advanced/Metastatic Hepatocellular Carcinoma | Phase 1 | Unknown | Liang Peng | 10 | 2021-01-25 | 2021-01-22 |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects Apatinib Mesylate, Repaglinide, Bupropion - Advanced Solid Tumor | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2020-11-16 | 2022-10-26 |
| Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection CT041 autologous CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody） - Gastric Adenocarcinoma, Pancreatic Cancer | Phase 1 / Phase 2 | Active not recruiting | CARsgen Therapeutics Co., Ltd. | 192 | 2020-10-23 | 2025-06-05 |
| A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. Apatinib in arm1, Rosuvastatin, Apatinib in arm2 - Solid Tumor, Adult | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 19 | 2020-07-27 | 2022-07-26 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） Fluzoparib, Apatinib - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2020-07-01 | 2020-12-09 |
| A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.), Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Zhejiang Cancer Hospital | 40 | 2020-07-01 | 2020-06-24 |
| A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function Apatinib Mesylate - Subjects With Impaired Renal Function and Healthy Subjects | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2020-06-05 | 2020-06-04 |
| Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients Apatinib Mesylate, Gefitinib - NSCLC | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 22 | 2020-05-26 | 2021-01-11 |
Showing 20 of 62. Sign in to see all of them.
Stomach Neoplasms (7) · Carcinoma, Hepatocellular (6) · Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (3) · Triple Negative Breast Neoplasms (3) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Carcinoma, Transitional Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Glioma (1)
Jiangsu HengRui Medicine Co., Ltd. (12) · Elevar Therapeutics (5) · Fudan University (2) · Fujian Cancer Hospital (2) · Sun Yat-sen University (2) · The First People's Hospital of Lianyungang (2) · Tianjin Medical University Second Hospital (2) · West China Hospital (2) · Zhejiang Cancer Hospital (2) · Zhongshan Hospital Xiamen University (2) · Anhui Provincial Hospital (1) · Bukwang Pharmaceutical (1) · CARsgen Therapeutics Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · China International Medical Foundation (1)
China (50) · United States (5) · South Korea (3)
Chen Yu (1) · Chengzhi Zhou, MD (1) · Dan Cao (1) · Dongsheng Zhang, M.D., Ph.D. (1) · Haitao Wang (1) · Haitao Wang, Ph.D (1) · Hongming Pan, MD (1) · Huiping Li, PhD (1) · Jian-Ming Xu, M.D. (1) · Jin Li, PhD (1) · Juan Li, MD (1) · Lai-ping Zhong, PHD (1) · Lei Zhang, PhD (1) · Li Liang, Prof. M.D. (1) · Li Xiao, Doctor (1)
PMID 20923544, PMID 38271925, PMID 18172173, PMID 18971936, PMID 21296855, PMID 21742485, PMID 23918952, PMID 29245310, PMID 30348638, PMID 32719455, PMID 32827353, PMID 35105939, PMID 36104359, PMID 36184642, PMID 36797744, PMID 37518060, PMID 37689733, PMID 37775744, PMID 38290515, PMID 38347177, PMID 38788174, PMID 39962074, PMID 40460847, PMID 42215704